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Abstract- Neonates, especially VLBW, are at 
high risk for sepsis related morbidity and mortality 
for immaturity of their immune system and invasive 
NICU practices. The paucity of immunoglobulins in 
preterm neonates consequently to the immaturity of 
immune system contributes to their high risk for 
systemic infection. The use of intravenous IgM 
enriched immunoglobulins, with higher 
antimicrobial activity than standard IgG, has been 
demonstrated in a retrospective study to reduce 
short term mortality in VLBW infant with proven 
sepsis. Larger, randomized  prospective  trials given 
the enormous burden of morbidity and mortality 
imposed by neonatal sepsis should urgently be 
addressed not only to validate this results  but also to 
tailor the optimal scheme of treatment. 
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I.  INTRODUCTION 
 
Neonatal sepsis still represents one of the main 
causes of mortality and morbidity among preterm 
especially very low birth weight (VLBW) infants [1-2]. 
Mortality in VLBW with septicemia can reach 50% [3].  
VLBW infants are prone to infections because of  
immaturity of their immune system, immunoglobulins 
and complement deficiencies, invasive practices in 
NICU and lack of maternal transplacental transport of 
IgG that usually occurs after 32 wk of gestation [3-5]. 
Antibiotic treatment also immediately started, 
sometimes failed to prevent death; administration of 
intravenous immunoglobulins in such neonates could 
improve immunitary functions [6].  
The fetus is in a condition of isolation and 
protection from the contact with microorganisms 
potentially responsible for infection, and  has a deeply 
immature immune system. Several components of the 
immune system appear early during gestation however 
they become completely functioning long after birth [7] 
and in straight relation to the increasing  gestational age. 
Consequently,  the newborn and the infant have a 
significant immunodeficiency and are exposed to the 
risk of serious infections. 
The reduced inflammatory response that 
characterizes the newborn also explains the lack of 
clinical signs of localization, such as fever or 
meningism, which often makes difficult to identify a 
systemic infection [8].  
 
 
II. INFECTION SUSCEPTIBILITY IN THE 
NEWBORN 
 
There are several factors that increase the 
susceptibility to infection in the newborn, especially if 
preterm and very low birth weight infant, such as 
immunological deficiencies, need for invasive, 
diagnostic and therapeutic procedures.  
A crucial role is played by the immaturity of 
the skin barrier. The skin of these infants is, in fact, 
immature and fragile, acting as an inadequate protective 
barrier against pathogens. Although skin rapidly 
matures after birth, its barrier function is compromised 
for more than 4 weeks; During this period, the infant 
experienced an excessive loss of transepidermic water 
[9], which is usually limited by applying 80% humidity 
in incubator, however this step at the same time 
promotes bacterial and fungal growth and colonization 
of the skin. Also respiratory and gastrointestinal 
mucosal appear immature and colonized by micro-
organisms that may have access through nasogastric and 
endotracheal cannulas normally used in such infants 
[10]. This occurs especially in relation to the deficit of 
secretory class A immunoglobulin, mucins and 
defensins, important in ensuring adequate mucosal 
defense. Also intestinal peristalsis and absorptive 
capacity are compromised and  levels of intraepitelial  
lymphocytes are reduced [11]. 
Innate immunity in the newborn, compared to 
the adult, is also impaired in numerous functions. 
Neutrophils and monocytes have less capacity of 
migrate to the inflammation site [7]; this occurs because 
the chemotactic activity, as well as the random 
migration, is inadequate. Phagocytosis and microbicidal 
activity are, however, similar to adult subjects [12,13]. 
The cytokines production, in particular IL-6 [14] and 
Translational Medicine @ UniSa - ISSN 2239-9747 2015, 11(5): 28-33 
 
29 
Università degli Studi di Salerno 
TNF-α [15], are compromised, and this justifies the 
reduced febrile response of the newborn. Although the 
percentage of NK cells in fetal blood is lower compared 
to the child or the adult, the absolute number is almost 
the same; however  they have a decreased activity, in 
particular  in the response to signaling [16]. The APC 
(antigens presenting cells), especially dendritic cells, 
also present a reduced function [17,18]; it would explain 
the impairment of T-mediated response in fetus and 
newborn [19,20].  
Non-specific humoral factors have lower serum 
concentrations than in adult. This deficit is the more 
pronounced the smaller the gestational age is. The fetal 
synthesis of complement proteins begins from the 5th - 
6th month of intrauterine life [12]; there is no evidence 
of  transplacentar transport [7, 21-23]. The levels of the 
various fractions are lower [7]; it depends on a lack of 
self-synthesis and is inversely related to gestational age. 
In term newborn activation of the classical pathway is 
altered in association to the opsonizing 
immunoglobulins deficiency while the alternative 
pathway acquires a compensatory role [12];  in preterm 
they are both compromised. This deficit, in association 
to  the reduction of phagocytic activity  can increase the 
possibility of acquiring serious infections, particularly 
from extracellular pathogens [19]. The right balance 
between pro-and anti-inflammatory cytokines appears to 
be essential for the elimination of the pathogen and the 
resolution of the same inflammatory state with minimal 
residual damage. When this does not occur both 
morbidity and mortality are markedly increased [24].  
Fetal thymus is a lymphoid organ active after 
the sixth week of gestation, characterized by an intense 
lymphopoiesis independent by the antigenic stimulus 
[25]. The production of T lymphocytes increases 
gradually during the second trimester, reaching normal 
values within the 30°-32° week, however, these cells are 
functionally inadequate: CD4 + T cells are able to 
generate clonal expansion, but are not sufficiently 
competent in helper function and the cytotoxic activity 
is considerably reduced [8].  
Another very important aspect is the deficiency 
of MHC class II molecules, a condition that persists for 
a long time and is correlated with increased 
susceptibility to infections. However it is necessary, in 
order to maintain the state of immunological tolerance, 
especially in early pregnancy, so that the product of 
conception is not recognized as foreign by the mother 
and then rejected [12]. B lymphocytes appear in fetal 
bone marrow, blood, liver and spleen before the 12th 
week of gestation, from this period begins the active 
placental transfer of maternal antibodies [26]. Only IgG 
can cross the placental barrier because of  their low 
molecular weight and the presence of specific receptors 
on the face of the placental chorionic villi. This allows 
the achievement in term newborn of IgG levels equal or 
even higher than the adult subject. In preterm infants, 
however, the antibody levels are much lower, the lower 
the gestational age is [12]. Therefore preterm [26] and 
VLBW infant [27] can present a significant 
hypogammaglobulinemia that inevitably exposes them 
to a greater risk of infection.  
At birth, most of immunoglobulins are maternal IgG, 
whose concentration decreases rapidly as a result of 
physiological catabolism and whose specificity is 
strongly dependent on the experience of maternal 
antigen.  
Infant antibody production begins around the 3rd month 
of life and by the age of 4-6 years IgG levels reach adult 
levels. The fetus is not able to produce IgA¸ therefore at 
birth mucous membranes are totally devoid of antibody 
defense and more susceptible to infections. However, 
colostrum, rich in secretory IgA, allows a valid 
compensation [12]. Newborn has an increased 
susceptibility to Gram-negative pathogens infection in 
relation to the absence  of maternal IgM transport, 
which act as heat-stable opsonins, and the low levels of 
C3b, heat-labile opsonin, that correlates  with the 
impaired phagocytic activity of polymorphonuclears. 
Maternal IgG can adequately compensate the function 
of heat-labile opsonin and provide protection against 
many Gram-negative pathogens, but not in the preterm 
infant that has deficient levels of immunoglobulins [16].  
 
 
III. IMMUNOGLOBULINS AS ADJUVANT 
TREATMENT IN SEPSIS 
 
Intravenous immunoglobulins supplementation 
could represent  an appealing strategy to fight neonatal 
sepsis especially in preterm and VLBW infant. 
Administration of intravenous 
immunoglobulins in such neonates could improve 
immunitary functions such as opsonisation, complement 
activity, antibody dependent-citotoxicity, and neutrophil 
chemoluminescence [28]. Several authors studied the 
role of immunoglobulins in the treatment of neonatal 
sepsis [29-31].  In 2010, a Cochrane metanalysis  has 
demonstrated that intravenous immunoglobulins 
administration significantly reduce mortality in neonates 
with suspected or proven infection [32] . Recently, the 
INIS study, an international, placebo-controlled, multi-
centre randomised trial that has enrolled 3493 infants 
and tested the adding of standard immunoglobulins (S-
IVIG) to antibiotic therapy in neonates with suspected 
infection showed that S-IVIG had no effect on death or 
major disability at the age of 2 years [33]. 
In theory, IgM-enriched IVIG (IgM-IVIG) 
have a higher antimicrobial activity than S-IVIG 
because of higher opsonization activity and activation of 
complement than IgG. A commercial formulation of 
IgM-IVIG, containing a high titre of IgM, IgA and IgG 
against both Gram- and Gram+ organisms [29] showed 
in animal and human studies that in models of Gram- 
bacteremia increases oxidative burst, reduces 
endothelial damage and liver and spleen colonization 
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[34].  In adult human patients with severe sepsis or 
septic shock a significant reduction in mortality as well 
as a significant decrease in a severity illness score 
(APACHE score) were found [35];  the IgM-enriched 
IVIG administration in combination with antibiotics 
showed an improvement of the survival of surgical ICU 
patients with abdominal sepsis [36]  A reduction of 
procalcitonin levels and days with fever  in patients with 
post-surgical infections treated with IgM-enriched IVIG 
were found [37]. A cost-effectiveness analysis also 
demonstrated that such product is a promising adjuvant 
therapy both clinically and economically for treatment 
of adults with severe sepsis and septic shock [38]. Few 
studies investigated the role of IgM-IVIG in neonates: 
Haque et al compared the use of  S-IVIG and IgM-IVIG 
and found a significant reduction of mortality in 
neonates treated with IgM-IVIG compared with those 
treated with S-IVIG and controls with a faster 
normalization of laboratory parameters in IgM-IVIG 
group [29]. The same authors in a previous study 
demonstrated a reduction of mortality in neonates (GA 
28-37 wk) with suspected sepsis treated with IgM-IVIG 
versus placebo [39]. There are no studies focused on the 
use of IgM-enriched IVIG in the treatment of sepsis in 
very low birth weight (VLBW) infants. 
 
 
  IV. USE OF IGM IVIG AS ADJUVANT  
TREATMENT IN SEPSIS OF VLBW INFANTS 
 
  Our group conducted a retrospective, cohort  study on 
the use of IgM-IVIG  in addition to antibiotic therapy in 
VLBW neonates with late onset sepsis as an hypothesis 
generator for future prospective clinical trials [40].  
All  VLBW infants enrolled were included  in the local 
section of the Vermont Oxford Network (VON) 
database from January 2008 to December 2012 for a 
total of  459 neonates reviewed. Neonates were born  at 
the University “Federico II” of Naples, the largest 
delivery place in the Naples regional area assisted by a 
level III NICU. Inclusion criteria was the diagnosis of  
blood culture-proven,  late  onset sepsis (i.e. sepsis 
occurring after 72 hours of life)  in VLBW infants. For  
defining blood culture as positive, we adopted the 
Vermont Oxford Network criteria, i.e.: 
- sepsis by coagulase negative staphylococcus: pathogen 
recovered from either a central line, or peripheral blood 
sample in association to one or more signs of 
generalized infection and treatment with 5 or more days 
of intravenous antibiotics after the above cultures were 
obtained;  
- sepsis by other bacteria: bacterial pathogen recovered 
from  blood culture; 
- sepsis by fungi: fungus recovered from a blood culture 
obtained from  either a central line or peripheral blood 
sample [41]. 
Clinical signs for the diagnosis were : apnoea, 
mottled skin, temperature instability, feeding 
intolerance, significant abdominal distension, 
respiratory distress or hemodynamic instability) . 
Laboratory index used were elevated CRP (cut off =1 
mg/dL), abnormal leukocyte count (cut off less than 
5.000/µl or more than 20.000/µl) and I/T  ratio (cut off  
>0.2). To assess the clinical severity of cases and 
controls at enrollment, we used the SNAP II score, a 
composite index of six physical parameters 
(hypotension, hypothermia, acidosis, PO2/ FiO2
 ratio, 
multiple seizures, urinary output) initially designed for 
NICU admission [42]. A recent study validated  the 
SNAP II score as a accurate mortality predictor at the 
onset of severe neonatal sepsis [43]. For this study, 
SNAP II score was calculated for each patients used the 
parameters found in the chart in the first 24 hours sepsis 
was suspected (i.e. when the clinical deterioration was 
reported, the blood exams were performed included 
blood culture and antibiotics were started). 
Exclusion criteria were: congenital anomalies,  
TORCH group infections, primary  immunodeficits.  
Intravenous antibacterial therapy used throughout the 
study was teicoplanin (loading dose 16 mg/Kg followed 
by 8 mg/Kg q 24 hours) and meropenem(20 mg/Kg q 8 
hours). In the event of a positive blood culture for 
Candida spp, antibiotic therapy was withdrawn and a 
standard antifungal regimen (liposomal amphotericin B: 
5 mg/kg/ die) was used  for 3 weeks.  
  Starting June 1st 2010,  IgM-IVIG 
(Pentaglobin® Biotest Pharma, Dreieich, Germany) 250 
mg /kg/die i.v. for three days was added to  the NICU 
protocol for sepsis treatment in the first 24 hours sepsis 
was suspected when antibiotic therapy was started. In 
order to compare neonates before and after the 
introduction of IgM-eIVIG in our clinical practice, 
meticulous care was exerted to ascertain that no other 
major change had been made that could have been 
relevant to the study outcome (i.e. central lines 
managing and duration; fluconazole prophylaxis against 
invasive fungal infections; handwashing and other 
general prophylactic measures; enteral nutrition). 
VLBW preterms with late onset sepsis may 
have a prolonged hospital stay  after a septic episode 
and their demise might be related to many factors other  
than  infection; therefore, short-term mortality (i.e. 
death within 7 and 21 days from treatment) was an 
appropriate primary outcome for this study. Secondary 
outcome measures were: in-hospital total mortality, 
rates of intraventricular hemorrhage, periventricular 
leukomalacia, necrotizing enterocolitis, 
bronchopulmonary dysplasia at discharge. 
Of the  82 VLBW infants enrolled, 2 neonates 
were excluded for congenital anomalies and one for 
TORCH infection; of the remaining 79 (see 
demographics in  Table 1), 40 patients received 
antibiotics in association  to IgM-IVIG and 39 received  
antibiotic treatment alone. No difference in birth weight,  
gestational age or SNAP II score was found. All 
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enrolled infants had a positive blood culture and the 
microbiology is given in figure 1.  
 








Figure  1. Main pathogens isolated from blood cultures 
 
 
Mortality at 7 and  21 days coincided.  IgM-
IVIG treated infants had a significantly lower short term 
mortality than untreated (OR 0.16; 95% CI: 0.3-0.7, 
p=0.005). Secondary outcomes were not significantly 
different between cases and controls (table 2).  
In a subgroup analysis of  neonates with 
Candida spp. sepsis, fewer short term deaths were also 
found for immunoglobulin treated neonates compared 
with untreated neonates. In fact 1/10 (10%) neonates 
died in treated group versus 8/15 (53%) deaths in 




TABLE 2. PRIMARY AND SECONDARY OUTCOMES OF THE 




V. CONSIDERATIONS ON THE USE OF IGM IVIG 
AS ADJUVANT  TREATMENT FOR SEPSIS IN 
VLBW INFANTS 
 
This pilot study  shows that IgM-IVIG are effective in 
reducing short-term mortality in VLBW infants with 
proven sepsis. When compared with S-IVIG, IgM-IVIG 
show more efficient complement activation, better 
opsonisation, greater neutralization of the streptococcal 
superantigen SpeA and  better binding both to bacterial 
antigens and  toxins all possibly due to their pentameric 
structure [44]. This biological background together with 
our retrospective observation may increase the interest 
towards this strategy  for IgM-IVIG in VLBW infants 
with sepsis despite the paucity and somewhat 
conflicting specific clinical evidence in the literature.  
With a bigger cohort we detect a clinically 
relevant difference focusing only on the most 
susceptible babies. Under the standard conditions of  
VON, we show an effect of  IgM-IVIG on short term 
mortality on those babies who had sepsis proved by 
positive blood culture. 
Unlike the Haque series, our most prevalent 
pathogens were fungi against which IgM-IVIG proved 
to be very effective. We later found out that our study 
preparation  had  an average anti- C. albicans specific 
titer of 1.618 U/ml of IgG, 171 U/ml of IgA, 194 U/ml 
of IgM (courtesy of the manifacturer).  
The explanation for this novel observation is possibly 
related to the fact that antibodies are a dominant 





n=39               p 
 
  
Gestational Age        
(weeks) 
27±2,6 27,6±3,9          NS 
Birth Weight  (grams) 924±277 951±362         NS 
Snap II Score 
15±13 12±9                NS 
Cesarean Section 39 (59%) 38 (58%)         NS 
Prenatal Steroids 32 (48%) 39 (60%)         NS 
CRP Positive 51 (77%) 49 (75%)         NS 
 
TREATED 
n = 40 
UNTREATED 
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In fact, antibody opsonization is crucial to optimal  
Candida phagocyting and killing by neutrophils and 
monocytes. Moreover, antibodies against Candida 
mannan antigens activate complement [45]. 
Despite the encouraging results, our study finds the 
main limitation in its observational nature; however, 
searching for confounders, we were not able to detect 
significant change of  NICU practices or outcome 
variations in the study period. Also, mortality is an 
immediate clear-cut endpoint.  
We believe  that this analysis fulfilled its original 
purpose to set  the ground for larger, randomized  
prospective  trials.  Given the enormous burden of 
morbidity and mortality imposed by neonatal sepsis, 
new research should urgently be addressed not only to 
validate our results  but also to tailor the optimal scheme 
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